These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 10404019)

  • 1. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
    J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections: Implications for detection of GH abuse.
    Krusenstjerna-Hafstrøm T; Rasmussen MH; Raschke M; Govender S; Madsen J; Christiansen JS
    Growth Horm IGF Res; 2011 Dec; 21(6):331-5. PubMed ID: 21963127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S; Riggs BL; Melton LJ; Achenbach SJ; Atkinson EJ; Khosla S
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
    Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
    Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
    Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
    J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary changes favorably affect bone remodeling in older adults.
    Heaney RP; McCarron DA; Dawson-Hughes B; Oparil S; Berga SL; Stern JS; Barr SI; Rosen CJ
    J Am Diet Assoc; 1999 Oct; 99(10):1228-33. PubMed ID: 10524386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate supplementation does not affect biochemical markers of bone turnover.
    Herrmann M; Stanger O; Paulweber B; Hufnagl C; Herrmann W
    Clin Lab; 2006; 52(3-4):131-6. PubMed ID: 16584059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
    Chlebna-Sokol D; Rusinska A
    Endocr Regul; 2001 Dec; 35(4):201-8. PubMed ID: 11858767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of low-dose prednisone on bone metabolism.
    Ton FN; Gunawardene SC; Lee H; Neer RM
    J Bone Miner Res; 2005 Mar; 20(3):464-70. PubMed ID: 15746991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.